JAK inhibitors show promise for AD

Emma Guttman-Yassky, MD, PhD

A new class of oral agents may be on the way for atopic dermatitis (AD). Early trials of Janus kinase (or JAK) inhibitors show promise in moderate to severe disease. Prednisone is currently the only FDA-approved oral-systemic treatment for AD.

Upadacitinib, a once daily JAK1 inhibitor, showed good differentiation between doses of 7.5 mg, 15 mg, 30 mg, and placebo in a phase 2 trial. Mean EASI scores improved 23% for placebo versus 74.4% for the 30 mg dose over the 16-week trial. A 72-week extension will be reported later.

“Even the lowest dose gave us good EASI 90 results while 50% of patients on the highest dose showed EASI 90,” said Emma Guttman-Yassky, MD, PhD, Sol and Clara Kest professor of dermatology, Icahn School of Medicine at Mount Sinai Medical Center. “And we saw no serious adverse events.”

Dr. Guttman-Yassky also presented data showing strong patient-reported outcomes for baricitinib, a JAK1/2 inhibitor approved for rheumatoid arthritis in the European Union and Japan.

ASN002, a first-in-class JAK/SYK inhibitor, showed 50% EASI 75 during a 29-day proof-of-concept trial with no study-related adverse events, said Robert Bissonnette, MD, MSc, president of Innovaderm.


Return to index